Plus Therapeutics (PSTV)
(Delayed Data from NSDQ)
$1.59 USD
-0.05 (-3.05%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $1.53 -0.06 (-3.77%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Plus Therapeutics, Inc. [PSTV]
Reports for Purchase
Showing records 1 - 19 ( 19 total )
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Strong Interim Results in LM; Multiple Upcoming Milestones in Q4; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Updates at SNO Highlight GBM and LM Potential; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Major Clinical Updates at SNO Meeting in November; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive LM Update; GBM Readout in November; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
First Signs of Survival Benefit in Leptomeningeal Metastases; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Promising Update With More to Come in 4Q; Adjust PT to $8.00; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Continued Clinical Progess With Readouts in 2H23; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pediatric and GBM Study Updates Expected in 2023; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Continued Progress on Clinical Fronts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Clarity on Clinical Path Going Forward; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Update Highlights LM Opportunity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Updates Expected in 2H22; Adjusting PT to $3.50; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Looking Ahead to Initial LMC Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Clinical Milestones Expected in 2022; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Major Upcoming Clinical Update at SNO; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Additional Cohort in ReSPECT Could Lead to Better Efficacy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Progress on New Studies and Indications in 2021; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Modernizing Radiotherapy Using Nanotechnology; Initiate With Buy and $7 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
|